These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31833419)

  • 1. Emerging Treatments for COPD: Evidence to Date on Revefenacin.
    Lal C; Khan A
    COPD; 2020 Feb; 17(1):112-119. PubMed ID: 31833419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.
    Donohue JF; Kerwin E; Sethi S; Haumann B; Pendyala S; Dean L; Barnes CN; Moran EJ; Crater G
    Respir Med; 2019 Jul; 153():38-43. PubMed ID: 31150963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
    Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
    Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
    Donohue JF; Kerwin E; Barnes CN; Moran EJ; Haumann B; Crater GD
    BMC Pulm Med; 2020 May; 20(1):134. PubMed ID: 32393215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD.
    Donohue JF; Mahler DA; Sethi S
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2947-2958. PubMed ID: 31908443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD).
    Donohue JF; Kerwin E; Sethi S; Haumann B; Pendyala S; Dean L; Barnes CN; Moran EJ; Crater G
    Respir Res; 2019 Oct; 20(1):241. PubMed ID: 31666076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease.
    Pudi KK; Barnes CN; Moran EJ; Haumann B; Kerwin E
    Respir Res; 2017 Nov; 18(1):182. PubMed ID: 29096627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revefenacin for the treatment of chronic obstructive pulmonary disease.
    Clark CM; Jacobs DM; Sethi S
    Expert Rev Respir Med; 2020 Mar; 14(3):239-247. PubMed ID: 31847629
    [No Abstract]   [Full Text] [Related]  

  • 9. Revefenacin for the treatment of chronic obstructive pulmonary disease.
    Li F; Yang J
    Expert Rev Clin Pharmacol; 2019 Apr; 12(4):293-298. PubMed ID: 30803279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials.
    Sethi S; Donohue JF; Ferguson GT; Barnes CN; Crater GD
    Ther Adv Respir Dis; 2020; 14():1753466620905278. PubMed ID: 32106777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials.
    Donohue JF; Feldman G; Sethi S; Barnes CN; Pendyala S; Bourdet D; Crater G
    Pulm Pharmacol Ther; 2019 Aug; 57():101808. PubMed ID: 31152911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease.
    Hvisdas C
    Am J Health Syst Pharm; 2021 Jun; 78(13):1184-1194. PubMed ID: 33821890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating revefenacin as a therapeutic option for chronic obstructive pulmonary disease.
    Antoniu SA; Rajnoveanu R; Ulmeanu R; Mihaltan F; Grigore M
    Expert Opin Pharmacother; 2020 Jun; 21(9):997-1004. PubMed ID: 32237914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety evaluation of revefenacin at the approved dose in patients with chronic obstructive pulmonary disease: A meta-analysis.
    Liu B; Zan S; Luo W
    Heart Lung; 2022; 52():52-60. PubMed ID: 34875569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease.
    Donohue JF; Ferguson GT; Ohar JA; Lombardi DA; Schneider RF; Johnson K
    Respir Med; 2023 Mar; 208():107123. PubMed ID: 36681255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues.
    Hegde SS; Pulido-Rios MT; Luttmann MA; Foley JJ; Hunsberger GE; Steinfeld T; Lee T; Ji Y; Mammen MM; Jasper JR
    Pharmacol Res Perspect; 2018 Jun; 6(3):e00400. PubMed ID: 29736245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung deposition of inhaled once-daily long-acting muscarinic antagonists
    Crater GD; Johnson K; Ward J; Backer J
    Ther Adv Respir Dis; 2022; 16():17534666221077561. PubMed ID: 35234085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revefenacin: First Global Approval.
    Heo YA
    Drugs; 2019 Jan; 79(1):85-91. PubMed ID: 30560478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety of glycopyrrolate/eFlow
    Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
    Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
    Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.